BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Shen Y, Yang J, Xu Z, Gu DY, Chen JF. Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis. World J Gastroenterol 2012; 18(21): 2712-2718 [PMID: 22690082 DOI: 10.3748/wjg.v18.i21.2712]
URL: https://www.wjgnet.com/1007-9327/full/v18/i21/2712.htm
Number Citing Articles
1
Antonia R. Sepulveda, Stanley R. Hamilton, Carmen J. Allegra, Wayne Grody, Allison M. Cushman-Vokoun, William K. Funkhouser, Scott E. Kopetz, Christopher Lieu, Noralane M. Lindor, Bruce D. Minsky, Federico A. Monzon, Daniel J. Sargent, Veena M. Singh, Joseph Willis, Jennifer Clark, Carol Colasacco, R. Bryan Rumble, Robyn Temple-Smolkin, Christina B. Ventura, Jan A. Nowak. Molecular Biomarkers for the Evaluation of Colorectal CancerThe Journal of Molecular Diagnostics 2017; 19(2): 187 doi: 10.1016/j.jmoldx.2016.11.001
2
Khalid El Bairi, Csongor Lengyel, Antonio Marra, Said Afqir. Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing2020; : 29 doi: 10.1007/978-3-030-53821-7_2
3
Vishal Das, Jatin Kalita, Mintu Pal. Predictive and prognostic biomarkers in colorectal cancer: A systematic review of recent advances and challengesBiomedicine & Pharmacotherapy 2017; 87: 8 doi: 10.1016/j.biopha.2016.12.064
4
Evangelia Razis, George Pentheroudakis, George Rigakos, Mattheos Bobos, George Kouvatseas, Olympia Tzaida, Thomas Makatsoris, Pavlos Papakostas, Maria Bai, Anna Goussia, Epaminontas Samantas, Demetrios Papamichael, Ourania Romanidou, Ioannis Efstratiou, Eleftheria Tsolaki, Amanda Psyrri, Wendy De Roock, Dimitrios Bafaloukos, George Klouvas, Sabine Tejpar, Konstantine T. Kalogeras, Dimitrios Pectasides, George Fountzilas. EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximabJournal of Cancer Research and Clinical Oncology 2014; 140(5): 737 doi: 10.1007/s00432-014-1626-2
5
Timothy L. Cannon, Megan A. Kokon, Sara Shafqat, John F. Deeken. RAS Mutations Beyond KRAS Exon 2: A Review and Discussion of Clinical Trial DataCurrent Treatment Options in Oncology 2015; 16(7) doi: 10.1007/s11864-015-0350-8
6
Antonia R. Sepulveda, Stanley R. Hamilton, Carmen J. Allegra, Wayne Grody, Allison M. Cushman-Vokoun, William K. Funkhouser, Scott E. Kopetz, Christopher Lieu, Noralane M. Lindor, Bruce D. Minsky, Federico A. Monzon, Daniel J. Sargent, Veena M. Singh, Joseph Willis, Jennifer Clark, Carol Colasacco, R. Bryan Rumble, Robyn Temple-Smolkin, Christina B. Ventura, Jan A. Nowak. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical OncologyArchives of Pathology & Laboratory Medicine 2017; 141(5): 625 doi: 10.5858/arpa.2016-0554-CP
7
Chia Wen Liu, Wen Jen Lin. Using doxorubicin and siRNA-loaded heptapeptide-conjugated nanoparticles to enhance chemosensitization in epidermal growth factor receptor high-expressed breast cancer cellsJournal of Drug Targeting 2013; 21(8): 776 doi: 10.3109/1061186X.2013.811511
8
Antonia R. Sepulveda, Stanley R. Hamilton, Carmen J. Allegra, Wayne Grody, Allison M. Cushman-Vokoun, William K. Funkhouser, Scott E. Kopetz, Christopher Lieu, Noralane M. Lindor, Bruce D. Minsky, Federico A. Monzon, Daniel J. Sargent, Veena M. Singh, Joseph Willis, Jennifer Clark, Carol Colasacco, R. Bryan Rumble, Robyn Temple-Smolkin, Christina B. Ventura, Jan A. Nowak. Molecular Biomarkers for the Evaluation of Colorectal CancerAmerican Journal of Clinical Pathology 2017; 147(3): 221 doi: 10.1093/ajcp/aqw209
9
Wen Jen Lin, Li Ting Kao. Cytotoxic enhancement of hexapeptide-conjugated micelles in EGFR high-expressed cancer cellsExpert Opinion on Drug Delivery 2014; 11(10): 1537 doi: 10.1517/17425247.2014.930433
10
Mohammad‐Javad Sanaei, Ayda Baghery Saghchy Khorasani, Atieh Pourbagheri‐Sigaroodi, Shabnam Shahrokh, Mohammad Reza Zali, Davood Bashash. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non‐coding RNAs, therapeutic opportunities, and the emerging role of nanoparticlesJournal of Cellular Physiology 2022; 237(3): 1720 doi: 10.1002/jcp.30655
11
Nele Boeckx, Ken Op de Beeck, Vanessa Deschoolmeester, Guy Van Camp, Patrick Pauwels, Marc Peeters. Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future PerspectivesCurrent Colorectal Cancer Reports 2014; 10(4): 380 doi: 10.1007/s11888-014-0242-5
12
Antonia R. Sepulveda, Stanley R. Hamilton, Carmen J. Allegra, Wayne Grody, Allison M. Cushman-Vokoun, William K. Funkhouser, Scott E. Kopetz, Christopher Lieu, Noralane M. Lindor, Bruce D. Minsky, Federico A. Monzon, Daniel J. Sargent, Veena M. Singh, Joseph Willis, Jennifer Clark, Carol Colasacco, R. Bryan Rumble, Robyn Temple-Smolkin, Christina B. Ventura, Jan A. Nowak. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical OncologyJournal of Clinical Oncology 2017; 35(13): 1453 doi: 10.1200/JCO.2016.71.9807
13
Christine Koulis, Raymond Yap, Rebekah Engel, Thierry Jardé, Simon Wilkins, Gemma Solon, Jeremy D. Shapiro, Helen Abud, Paul McMurrick. Personalized Medicine—Current and Emerging Predictive and Prognostic Biomarkers in Colorectal CancerCancers 2020; 12(4): 812 doi: 10.3390/cancers12040812
14
Olorunseun O. Ogunwobi, Fahad Mahmood, Akinfemi Akingboye. Biomarkers in Colorectal Cancer: Current Research and Future ProspectsInternational Journal of Molecular Sciences 2020; 21(15): 5311 doi: 10.3390/ijms21155311
15
Lillian M. Smyth, Kelsey R. Monson, Komal Jhaveri, Alexander Drilon, Bob T. Li, Wassim Abida, Gopa Iyer, John F. Gerecitano, Mrinal Gounder, James J. Harding, Martin H. Voss, Vicky Makker, Alan L. Ho, Pedram Razavi, Alexia Iasonos, Philip Bialer, Mario E. Lacouture, Jerrold B. Teitcher, Joseph P. Erinjeri, Nora Katabi, Matthew G. Fury, David M. Hyman. A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxelInvestigational New Drugs 2017; 35(6): 742 doi: 10.1007/s10637-017-0445-0
16
Zhiqiang Cai, Fuxiang Zhou. A novel Anoikis and immune-related genes marked prognostic signature for colorectal cancerMedicine 2022; 101(46): e31127 doi: 10.1097/MD.0000000000031127
17
Zeinab Safarpour Lima, Mostafa Ghadamzadeh, Farzad Tahmasebi Arashloo, Ghazaleh Amjad, Mohammad Reza Ebadi, Ladan Younesi. Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigmsJournal of Hematology & Oncology 2019; 12(1) doi: 10.1186/s13045-019-0725-6